- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00528489
Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-B (Gag, Pol, Env) Given Alone, With IL-12 DNA, or With a Dose Escalation of IL-15 DNA, in Healthy, HIV-1-uninfected Adults Participants
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
A vaccine that is effective against multiple strains of HIV remains the best option for preventing the spread of HIV. Plasmid DNA vaccines are inexpensive and easy to construct. When DNA vaccines are administered in combination with cytokines, such as IL-12 or IL-15, the immune response to the vaccine is increased. The purpose of this study is to determine the safety and tolerability of the DNA plasmid vaccine, PENNVAX-B when administered alone, or with IL-12 or IL-15 DNA adjuvants. The most effective and safe dose of IL-15 will also be determined during this study.
This study will last approximately 12 months. Participants will be randomly assigned to one of four groups. Group 1 will receive an injection of PENNVAX-B combined with 0.8 mg IL-15 in each deltoid or placebo. Group 2 will receive an injection of PENNVAX-B alone or placebo. Group 3 will receive an injection of PENNVAX-B combined with IL-12 in each deltoid or placebo. Group 4 will receive PENNVAX-B combined with 2 mg IL-15 or placebo. Injections will occur at study entry, Months 1, 3, and 6. Additional study visits will occur on Days 14, 42, 98, 182, 273, and 364. At these visits a brief physical, blood collection, interview, and risk reduction counseling will occur. At some visits HIV testing, urine collection, and pregnancy tests will also occur.
As of 05/30/08, participants will be enrolled into Groups 3 and 4 at a limited pace to allow for additional safety reviews for the first few participants in these groups. Additionally, safety data will be reviewed for Groups 1 and 2 to determine whether the remainder of participants in Groups 2, 3, and 4 will be enrolled.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- Alabama Vaccine CRS
-
-
California
-
San Francisco, California, Vereinigte Staaten
- San Francisco Vaccine and Prevention CRS
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten
- Brigham and Women's Hosp. CRS
-
-
New York
-
Bronx, New York, Vereinigte Staaten, 10456
- NY Blood Ctr./Bronx CRS
-
New York, New York, Vereinigte Staaten, 10003
- NY Blood Ctr./Union Square CRS
-
New York, New York, Vereinigte Staaten, 10032
- HIV Prevention & Treatment CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten
- 3535 Market Street CRS
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten
- Vanderbilt Vaccine CRS
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- HIV-1 and -2 uninfected
- Willing to receive HIV test results
- Good general health
- Certain laboratory values within normal range or with site physician approval
- Negative for Hepatitis B surface antigen
- Negative Hepatitis C test
- Willing to use acceptable methods of contraception
Exclusion Criteria:
- HIV vaccines or placebos in prior HIV trial. Participants who can provide documentation that they received a placebo in a prior HIV trial may be eligible.
- Immunosuppressive medications within 168 days prior to first study vaccination. Participants using corticosteroid nasal spray for allergies or topical corticosteroids for mild, uncomplicated dermatitis are not excluded.
- Blood products within 120 days prior to first study vaccination
- Receipt of immunoglobulin within 60 days prior to first vaccination
- Live attenuated vaccines within 30 days prior to first study vaccination
- Any vaccine that is not a live attenuated vaccine within 14 days prior to first study vaccination
- Investigational research agents within 60 days prior to first study vaccination
- Current anti-tuberculosis (TB) preventive therapy or treatment clinically significant medical condition, abnormal physical exam findings, abnormal laboratory results, or past medical history that may affect current health. More information about this criterion can be found in the protocol.
- Any medical, psychiatric, social, occupational, or other condition or responsibility that in the opinion of the investigator would interfere with the study. More information about this criterion can be found in the protocol.
- Allergy to amide-type local anesthetics
- Serious adverse reactions to vaccines
- Autoimmune disease or immunodeficiency
- Active syphilis infection. Participants who have been fully treated for syphilis over 6 months prior to study entry are not excluded.
- Asthma other than mild, well-controlled asthma. More information on this criterion can be found in the protocol.
- Type 1 or type 2 diabetes mellitus. Participants with histories of isolated gestational diabetes are not excluded.
- Thyroidectomy or thyroid disease requiring medication during the 12 months prior to study entry
- Accumulation of fluid in the blood vessels (angioedema) within 3 years prior to study entry if episodes are considered serious or have required medication in the 2 years prior to study entry
- Uncontrolled hypertension
- Body Mass Index of 40 or greater OR of 35 or greater if certain other criteria apply. More information about these criteria can be found in the protocol
- Bleeding disorder
- Cancer. Participants with surgically removed cancer that is unlikely to recur are not excluded.
- Seizure disorder
- Absence of the spleen
- Pregnancy or breastfeeding
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: 1
PENNVAX-B with 0.8 mg IL-15 administered in both deltoids at Months 0, 1, 3, and 6
|
DNA vaccine containing the HIV genes Gag, Pol, and Env
Cytokine injection
|
Experimental: 2
PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
|
DNA vaccine containing the HIV genes Gag, Pol, and Env
|
Experimental: 3
PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
|
DNA vaccine containing the HIV genes Gag, Pol, and Env
Cytokine injection
|
Experimental: 4
PENNVAX-B with 2 mg IL-15 injected into both deltoids at Months 0, 1, 3, and 6
|
DNA vaccine containing the HIV genes Gag, Pol, and Env
Cytokine injection
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Safety data including local and systemic reactogenicity sign and symptoms, laboratory measures of safety, and adverse and serious adverse events
Zeitfenster: Throughout study
|
Throughout study
|
Safety data from Groups 1 and 4
Zeitfenster: Throughout study
|
Throughout study
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
HIV-1 specific interferon gamma ELISpot and/or intracellular cytokine staining T cell response
Zeitfenster: 2 weeks after 3rd and 4th vaccinations
|
2 weeks after 3rd and 4th vaccinations
|
HIV-1 specific neutralizing and binding antibody assays
Zeitfenster: 2 weeks after 3rd and 4th vaccinations
|
2 weeks after 3rd and 4th vaccinations
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: Scott Parker, MD, HVTN, FHCRC
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Vaccine. 2015 May 11;33(20):2347-53. doi: 10.1016/j.vaccine.2015.03.036. Epub 2015 Mar 25.
- Johnston MI, Fauci AS. An HIV vaccine--evolving concepts. N Engl J Med. 2007 May 17;356(20):2073-81. doi: 10.1056/NEJMra066267. No abstract available.
- Ogawa H, Ueno M, Uchibori H, Matsumoto I, Seno N. Direct carbohydrate analysis of glycoproteins electroblotted onto polyvinylidene difluoride membrane from sodium dodecyl sulfate-polyacrylamide gel. Anal Biochem. 1990 Nov 1;190(2):165-9. doi: 10.1016/0003-2697(90)90175-9.
- McBurney SP, Ross TM. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines. Curr Pharm Des. 2007;13(19):1957-64. doi: 10.2174/138161207781039841.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- HIV-Infektionen
Andere Studien-ID-Nummern
- HVTN 070
- 10490 (Andere Kennung: CTEP)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen
Klinische Studien zur PennVax B
-
Inovio PharmaceuticalsAbgeschlossenHIV-Infektionen | HIV-1-InfektionVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-InfektionenVereinigte Staaten
-
University of PennsylvaniaDrexel UniversityAbgeschlossenHIV infektionVereinigte Staaten
-
Steven DeeksNational Institute of Allergy and Infectious Diseases (NIAID); University of... und andere MitarbeiterAbgeschlossen
-
National Institute of Allergy and Infectious Diseases...Abgeschlossen
-
National Institute of Allergy and Infectious Diseases...Dynavax Technologies CorporationAktiv, nicht rekrutierendHIV infektion | Hepatitis BVereinigte Staaten, Haiti, Botswana, Philippinen, Thailand, Brasilien, Kenia, Malawi, Indien, Südafrika, Uganda, Vietnam
-
BioNTech SEAbgeschlossenCOVID-19 | SARS-CoV2-Infektion | SARS-CoV-2 Akute Atemwegserkrankung | SARS (Krankheit)Vereinigte Staaten, Deutschland, Truthahn, Südafrika
-
Brigham and Women's HospitalNoch keine RekrutierungErnährungsgewohnheitenVereinigte Staaten
-
Indiana UniversityAlcon ResearchAbgeschlossenKurzsichtigkeit | WeitsichtigkeitVereinigte Staaten
-
ChemoCentryxMedpace, Inc.AbgeschlossenFokale segmentale Glomerulosklerose | FSGS | GlomeruloskleroseVereinigte Staaten, Frankreich, Italien, Australien, Vereinigtes Königreich, Kanada, Neuseeland, Polen